Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Academic Article uri icon

start page

  • 537

end page

  • 543


  • Substantial weight gain is common with many atypical antipsychotics.To evaluate the extent, time course and predictors of weight gain and its effect on study retention among people with first-episode psychosis treated with olanzapine or haloperidol.Survival analysis assessed time to potentially clinically significant weight gain (> or =7%) and the effect of weight gain on study retention. Weight gain during the 2-year study was summarised using last-observation-carried-forward (LOCF), observed cases and study completion approaches.After 2 years of treatment, LOCF mean weight gain was 10.2 kg (s.d.=10.1) for olanzapine (n=131) and 4.0 kg (s.d.=7.3) for haloperidol (n=132); observed cases mean weight gain was 15.4 kg (s.d.=10.0) for olanzapine and 7.5 kg (s.d.=9.2) for haloperidol. Change in body mass index was significantly predicted only by treatment group (P < 0.0001).Olanzapine was associated with significantly greater weight gain than haloperidol, with both leading to greater weight gain than previously described.

date/time value

  • December 2005

Digital Object Identifier (DOI)

  • 10.1192/bjp.187.6.537

PubMed Identifier

  • 16319406


  • 187



  • Adult
  • Antipsychotic Agents
  • Benzodiazepines
  • Body Mass Index
  • Cholesterol
  • Double-Blind Method
  • Female
  • Haloperidol
  • Humans
  • Male
  • Patient Dropouts
  • Schizophrenia
  • Time Factors
  • Treatment Outcome
  • Weight Gain